If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.205    0.00 (0.00%)
Bid:
1.14
Ask:
1.34
Spread: 0.20 (17.544%)
Market Cap: £28.27m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

Product Launch

16 Dec 2005 07:00

Provexis PLC16 December 2005 PROVEXIS PLC ("Provexis" or the "Company") UK Launch of Sirco(TM) Provexis, the nutraceutical company that develops scientifically-provenfunctional and medical foods, is delighted to confirm the launch of itsSirco(TM) heart health juice drink in the UK in January 2006. The Company has so far secured an initial distribution base with two of the fivelargest supermarket retailers in the UK, which for reasons of commercialconfidentiality cannot be named at present. Both retailers will distributeSirco(TM) nationally. Within the larger of the two supermarket groups, Sirco(TM)will be initially available in premier stores which represent, by weighteddistribution, approximately 35 per cent. of their total UK distribution base.Within the second supermarket chain, Sirco(TM) will be initially available, byweighted distribution, across 70 per cent. of their total UK distribution base.Both retailers will stock Sirco(TM) in one litre packs of both flavour variants,Apple & Blueberry and Orange, and the drink will be located in the chilled fruitjuice section. The Company is in on-going discussions with a number of other retailers andhopes to make further distribution announcements in 2006. In addition to the onelitre packs, the Company is also developing a 250ml bottle of Sirco(TM) fordistribution to retailers in mid 2006. This bottle will have an extended shelflife and is intended to widen the distribution base to include independentchemists, convenience stores and food service industry channels such as health,education and travel outlets. Sirco(TM) is the first heart health product to contain the patentedFruitflow(TM) technology. Fruitflow(TM) was developed by Provexis in order tohelp regular "healthy" consumers reduce the risk of heart attack and stroke. Thenatural bioactive works by reducing blood platelet aggregation ("thinning theblood"), a significant contributing factor to a thrombosis (internal bloodclot). Sirco(TM) carries the health claim "Helps to Maintain a Healthy Heart andBenefits Circulation" and is approved by the leading heart health charity, HEARTUK. Commenting on the forthcoming launch Dr Stephen Franklin, CEO of Provexis, said: "This marks a significant milestone for Provexis and we are delighted that wehave secured distribution with two of the largest UK supermarkets. Bothretailers are ideal outlets in terms of the demographics and target market forthis product. We will be investing in media advertising as well as in-storeactivity to ensure we maximise this substantial opportunity. We look forward to growing the retailer base for Sirco(TM) throughout 2006,whilst in parallel securing licensing arrangements with major international foodpartners to integrate the FruitFlow(TM) technology into new food products inglobal markets." For further information please contact: Provexis plcDr Stephen Franklin 020 8392 6631 Bell Pottinger Corporate & FinancialAnn-Marie Wilkinson/Emma Kent 020 7861 3232 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Feb 20117:00 amRNSDevelopment Agreement with DSM Nutritional Product
8th Feb 20114:35 pmRNSPrice Monitoring Extension
16th Dec 20107:00 amRNSINTERIM RESULTS
9th Dec 20107:00 amRNSNotice of Results
17th Nov 20107:00 amRNSFruitflow wins industry innovation awards
29th Oct 20107:00 amRNSTotal Voting Rights
27th Oct 20104:40 pmRNSSecond Price Monitoring Extn
27th Oct 20104:35 pmRNSPrice Monitoring Extension
14th Oct 20101:38 pmRNSHolding(s) in Company
11th Oct 201011:53 amRNSHolding(s) in Company
4th Oct 20107:00 amRNSIssue of Equity
13th Sep 20104:24 pmRNSHolding(s) in Company
9th Sep 20103:17 pmRNSResult of AGM
9th Sep 20107:00 amRNSAGM Statement
7th Sep 20104:40 pmRNSSecond Price Monitoring Extn
7th Sep 20104:35 pmRNSPrice Monitoring Extension
6th Sep 20104:35 pmRNSPrice Monitoring Extension
13th Aug 20107:00 amRNSAnnual report & accounts and notice of AGM
28th Jul 20104:40 pmRNSSecond Price Monitoring Extn
28th Jul 20104:35 pmRNSPrice Monitoring Extension
26th Jul 201011:35 amRNSNOTIFICATION OF MAJOR INTEREST IN SHARES
26th Jul 20107:00 amRNSProduct Update
23rd Jul 20104:40 pmRNSSecond Price Monitoring Extn
23rd Jul 20104:35 pmRNSPrice Monitoring Extension
22nd Jul 20104:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20104:35 pmRNSPrice Monitoring Extension
14th Jul 20104:40 pmRNSSecond Price Monitoring Extn
14th Jul 20104:35 pmRNSPrice Monitoring Extension
8th Jul 20104:40 pmRNSSecond Price Monitoring Extn
8th Jul 20104:35 pmRNSPrice Monitoring Extension
28th Jun 20104:40 pmRNSSecond Price Monitoring Extn
28th Jun 20104:35 pmRNSPrice Monitoring Extension
22nd Jun 20107:00 amRNSDraw Down of Funds and Issue of Equity
15th Jun 20104:40 pmRNSSecond Price Monitoring Extn
15th Jun 20104:35 pmRNSPrice Monitoring Extension
10th Jun 20104:40 pmRNSSecond Price Monitoring Extn
10th Jun 20104:35 pmRNSPrice Monitoring Extension
1st Jun 20107:00 amRNSFinal Results
1st Jun 20107:00 amRNSAlliance agreement with DSM Nutritional Products
28th May 20103:20 pmRNSNotice of Results
26th Apr 20107:00 amRNSRe Agreement
21st Apr 20107:00 amRNSChange in major shareholding
21st Apr 20107:00 amRNSNotification of Major Interest in Shares
13th Apr 201012:01 pmRNSHolding(s) in Company
31st Mar 20104:35 pmRNSTotal Voting Rights
31st Mar 20107:00 amRNSPre-close trading update
31st Mar 20107:00 amRNSCompletion of ?25m Equity Financing Facility
9th Mar 20107:00 amRNSTrial Results
18th Feb 201011:30 amRNSHolding(s) in Company
12th Feb 20103:20 pmRNSDirector Shareholdings and Additional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.